221 related articles for article (PubMed ID: 24860782)
21. Ontogeny of expression of transforming growth factor-beta and its receptors and their possible relationship with scarless healing in human fetal skin.
Chen W; Fu X; Ge S; Sun T; Zhou G; Jiang D; Sheng Z
Wound Repair Regen; 2005; 13(1):68-75. PubMed ID: 15659038
[TBL] [Abstract][Full Text] [Related]
22. Chamaejasmenin B, a novel candidate, inhibits breast tumor metastasis by rebalancing TGF-beta paradox.
Li Q; Wang Y; Xiao H; Li Y; Kan X; Wang X; Zhang G; Wang Z; Yang Q; Chen X; Weng X; Chen Y; Zhou B; Guo Y; Liu X; Zhu X
Oncotarget; 2016 Jul; 7(30):48180-48192. PubMed ID: 27374079
[TBL] [Abstract][Full Text] [Related]
23. The TGF-beta paradox in human cancer: an update.
Tian M; Schiemann WP
Future Oncol; 2009 Mar; 5(2):259-71. PubMed ID: 19284383
[TBL] [Abstract][Full Text] [Related]
24. The interaction of endoglin with beta-arrestin2 regulates transforming growth factor-beta-mediated ERK activation and migration in endothelial cells.
Lee NY; Blobe GC
J Biol Chem; 2007 Jul; 282(29):21507-17. PubMed ID: 17540773
[TBL] [Abstract][Full Text] [Related]
25. Respective roles of the mitogen-activated protein kinase (MAPK) family members in pancreatic stellate cell activation induced by transforming growth factor-β1 (TGF-β1).
Xu XF; Liu F; Xin JQ; Fan JW; Wu N; Zhu LJ; Duan LF; Li YY; Zhang H
Biochem Biophys Res Commun; 2018 Jun; 501(2):365-373. PubMed ID: 29705706
[TBL] [Abstract][Full Text] [Related]
26. Stimulation of pro-alpha(1)(I) collagen by TGF-beta(1) in mesangial cells: role of the p38 MAPK pathway.
Chin BY; Mohsenin A; Li SX; Choi AM; Choi ME
Am J Physiol Renal Physiol; 2001 Mar; 280(3):F495-504. PubMed ID: 11181412
[TBL] [Abstract][Full Text] [Related]
27. A tumor suppressor role for PP2A-B56alpha through negative regulation of c-Myc and other key oncoproteins.
Arnold HK; Sears RC
Cancer Metastasis Rev; 2008 Jun; 27(2):147-58. PubMed ID: 18246411
[TBL] [Abstract][Full Text] [Related]
28. Concurrent inhibition of TGF-β and mitogen driven signaling cascades in Dupuytren's disease - non-surgical treatment strategies from a signaling point of view.
Krause C; Kloen P
Med Hypotheses; 2012 Mar; 78(3):385-8. PubMed ID: 22196988
[TBL] [Abstract][Full Text] [Related]
29. Transforming growth factor β and Ras/MEK/ERK signaling regulate the expression level of a novel tumor suppressor Lefty.
Miyata N; Azuma T; Hozawa S; Higuchi H; Yokoyama A; Kabashima A; Igarashi T; Saeki K; Hibi T
Pancreas; 2012 Jul; 41(5):745-52. PubMed ID: 22441145
[TBL] [Abstract][Full Text] [Related]
30. KLF11 mediates a critical mechanism in TGF-beta signaling that is inactivated by Erk-MAPK in pancreatic cancer cells.
Ellenrieder V; Buck A; Harth A; Jungert K; Buchholz M; Adler G; Urrutia R; Gress TM
Gastroenterology; 2004 Aug; 127(2):607-20. PubMed ID: 15300592
[TBL] [Abstract][Full Text] [Related]
31. A control engineering approach to understanding the TGF-β paradox in cancer.
Chung SW; Cooper CR; Farach-Carson MC; Ogunnaike BA
J R Soc Interface; 2012 Jun; 9(71):1389-97. PubMed ID: 22188767
[TBL] [Abstract][Full Text] [Related]
32. ShcA Protects against Epithelial-Mesenchymal Transition through Compartmentalized Inhibition of TGF-β-Induced Smad Activation.
Muthusamy BP; Budi EH; Katsuno Y; Lee MK; Smith SM; Mirza AM; Akhurst RJ; Derynck R
PLoS Biol; 2015 Dec; 13(12):e1002325. PubMed ID: 26680585
[TBL] [Abstract][Full Text] [Related]
33. Sphingosylphosphorylcholine stimulates expression of fibronectin through TGF-beta1-Smad-dependent mechanism in human mesenchymal stem cells.
Moon HJ; Jeon ES; Kim YM; Lee MJ; Oh CK; Kim JH
Int J Biochem Cell Biol; 2007; 39(6):1224-34. PubMed ID: 17481939
[TBL] [Abstract][Full Text] [Related]
34. TLR4 ligand/H₂O₂ enhances TGF-β1 signaling to induce metastatic potential of non-invasive breast cancer cells by activating non-Smad pathways.
Zhou YH; Liao SJ; Li D; Luo J; Wei JJ; Yan B; Sun R; Shu Y; Wang Q; Zhang GM; Feng ZH
PLoS One; 2013; 8(5):e65906. PubMed ID: 23734265
[TBL] [Abstract][Full Text] [Related]
35. Hypoxia-activated Smad3-specific dephosphorylation by PP2A.
Heikkinen PT; Nummela M; Leivonen SK; Westermarck J; Hill CS; Kähäri VM; Jaakkola PM
J Biol Chem; 2010 Feb; 285(6):3740-3749. PubMed ID: 19951945
[TBL] [Abstract][Full Text] [Related]
36. The role for transforming growth factor-beta (TGF-beta) in human cancer.
Gold LI
Crit Rev Oncog; 1999; 10(4):303-60. PubMed ID: 10654929
[TBL] [Abstract][Full Text] [Related]
37. HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells.
Wilson CA; Cajulis EE; Green JL; Olsen TM; Chung YA; Damore MA; Dering J; Calzone FJ; Slamon DJ
Breast Cancer Res; 2005; 7(6):R1058-79. PubMed ID: 16457687
[TBL] [Abstract][Full Text] [Related]
38. TGF-beta signal transduction in corneal wound healing as a therapeutic target.
Saika S
Cornea; 2004 Nov; 23(8 Suppl):S25-30. PubMed ID: 15448476
[TBL] [Abstract][Full Text] [Related]
39. Quantitative modeling and analysis of the transforming growth factor beta signaling pathway.
Chung SW; Miles FL; Sikes RA; Cooper CR; Farach-Carson MC; Ogunnaike BA
Biophys J; 2009 Mar; 96(5):1733-50. PubMed ID: 19254534
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical analysis of major TGF-beta isoforms and their receptors in laryngeal carcinomas.
Hagedorn H; Elbertzhagen A; Ruoss I; Sauer U; Nerlich AG
Virchows Arch; 2001 Oct; 439(4):531-9. PubMed ID: 11710640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
